VIKING THERAPEUTICS Aktie

 

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans....

Viking Therapeutics, Inc. (VKTX) reached $36.37 at the closing of the latest trading day, reflecting a -3.81% change compared to its last close....

Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting a -5.54% change compared to its last close....

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal....

Die Erfolge von Novo Nordisk und Eli Lilly haben dazu geführt, dass viele Biopharma-Unternehmen in die Adipositas-Forschung eingestiegen sind. Viking Therapeutics hingegen widmet sich schon länger metabolischen Erkrankungen. Nach mehreren Monaten der Lethargie übernehmen wieder die Bullen das Zepter bei der Biotech-Aktie....

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet....

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here's how their financials and risk profiles compare....

This biotech might have a bright future, but it'll need to survive against the incumbents to do so....

The stock is known to soar on good news....

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug....

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day....

That would be an impressive run if it could get there soon....

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare....

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day....

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735....

Viking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien....

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage......

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns....

The drugmaker is looking to challenge the leaders in the weight loss market....